Key Highlights

  • Healius (ASX:HLS) traded at A$0.50 during the 6 November 2026 session, up 1.01%.
  • On 25 September 2026 Healius agreed to sell Agilex Biolabs to Novotech.
  • The Enterprise value is A$160 million, with completion expected in H2 FY27, subject to conditions.

Healius (ASX:HLS) shares were quoted at A$0.50 during the 6 November 2026 trading session, up 1.01%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 25 September 2026 sale announcement. Healius is an ASX-listed healthcare company with pathology and other healthcare services.

Latest Developments

Agreement to Sell Agilex Biolabs to Novotech (released 25 September 2026)

Healius agreed to sell Agilex Biolabs to Novotech for an enterprise value of A$160 million. Completion is expected during the second half of FY27, subject to satisfaction of certain conditions.

About the Company

Healius is an ASX-listed healthcare company headquartered in Sydney, with businesses in pathology and other healthcare services.

Business Overview

Agilex Biolabs is a clinical research business. Its sale would reshape the Healius portfolio, with proceeds and Capital allocation details to be set out by the company.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Healthcare services companies are affected by portfolio reshaping, funding and reimbursement settings. Disposals can change the scale of remaining operations.

Risks to Watch

Completion depends on conditions, and the timing is set for H2 FY27. The sale would change the scale of the business, and the final proceeds and use of funds are not set out in the announcement.

Catalysts on Watch

Investors may follow completion of the Agilex sale, the use of proceeds and the company's next financial result.

Final Takeaways

Healius (ASX:HLS) traded higher on 6 November 2026 in a session where the health care index eased. Its sale agreement, dated 25 September 2026, is separate from the session move.